Table 2.
Organ or tissue | wT | Cancer site | Boy |
Girl |
||
---|---|---|---|---|---|---|
IT/HT (% Sv−1) | MT/HT (% Sv−1) | IT/HT (% Sv−1) | MT/HT (% Sv−1) | |||
Gonads | 0.20 | Ovary | 0.7 | 0.4 | ||
Red bone marrow | 0.12 | Leukemia | 1.2 | 0.7 | 0.9 | 0.5 |
Colon | 0.12 | Colon | 2.4 | 1.2 | 1.6 | 0.7 |
Lungs | 0.12 | Lung | 2.2 | 2.2 | 5.0 | 4.4 |
Stomach | 0.12 | Stomach | 0.6 | 0.3 | 0.7 | 0.4 |
Bladder | 0.05 | Bladder | 1.5 | 0.3 | 1.5 | 0.4 |
Breasts | 0.05 | Breast | 7.1 | 1.7 | ||
Liver | 0.05 | Liver | 0.4 | 0.3 | 0.2 | 0.2 |
Esophagus | 0.05 | |||||
Thyroid | 0.05 | Thyroid | 0.5 | 2.8 | ||
Skin | 0.01 | Skin | See the text | |||
Bone surface | 0.01 | |||||
Remainder | 0.05 | Other | 5.0 | 2.0 | 5.2 | 2.2 |
Blank values were taken as zero because they were not included in Tables 12D-1 and 12D-2 in the BEIR VII Report. Although specific risk coefficients were also available for cancers of the prostate and uterus, these SMN sites were neglected because the values of equivalent dose in these organs were minimal and the risk coefficients were small.